title: Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
abstract: Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.
authors.affiliation: VIB Center for the Biology of Disease, Leuven, Belgium.
authors.forename: Ina
authors.initials: I
authors.lastname: Tesseur
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Lo
authors.forename: Anouk
authors.initials: A
authors.lastname: Roberfroid
authors.forename: Sofie
authors.initials: S
authors.lastname: Dietvorst
authors.forename: Bianca
authors.initials: B
authors.lastname: Van Broeck
authors.forename: Marianne
authors.initials: M
authors.lastname: Borgers
authors.forename: Harrie
authors.initials: H
authors.lastname: Gijsen
authors.forename: Diederik
authors.initials: D
authors.lastname: Moechars
authors.forename: Marc
authors.initials: M
authors.lastname: Mercken
authors.forename: John
authors.initials: J
authors.lastname: Kemp
authors.forename: Rudi
authors.initials: R
authors.lastname: D'Hooge
authors.forename: Bart
authors.initials: B
authors.lastname: De Strooper
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D008297:Male; D013764:Tetrahydronaphthalenes / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D013764:Tetrahydronaphthalenes